|
Hearken to this text |
The Genesis RMN System features flexible robotic arms that securely hold Genesis magnets, enabling precision adjustments for optimal system and related imaging angles. | Supply: Stereotaxis
Stereotaxis Inc. This week, Intuitive announced that its Genesis surgical robotic system has secured regulatory approval in China. The corporation noted that its system provides secure and precise cardiac ablation treatments for managing arrhythmias effectively.
The Genesis implant utilizes small magnetic rotors situated adjacent to its hermetically sealed mass, thereby enabling real-time responsiveness to physician-directed programming. Utilizing advanced, durable robotic arms, brokers are enabled to expand their range of motion and accommodate broader X-ray positioning, as stated by Stereotaxis.
By 1990, Stereotaxis had pioneered the development of innovative surgical robots for facilitating minimally invasive endovascular interventions. The St. The St. Louis-based company noted that its innovative approach enables seamless access to minimally invasive treatments, enhancing productivity, connectivity, and intelligence within the operating room.
China market
The Chinese Nationwide Medical Merchandise Administration has approved a joint application from Stereotaxis and Shanghai MicroPort EP Medtech Co., paving the way for their collaborative medical product to reach the market nationwide? For the Genesis Robotic Magnetic Navigation (RMN) System? Stereotaxis has hailed the development as a vital milestone, marking a significant expansion of minimally invasive robotic expertise in China.
For strategic partnerships and market penetration opportunities in the Chinese market.
Stereotaxis Chairman and CEO David Fischel expressed his excitement, stating, “We are thrilled to have obtained NMPA clearance for our Genesis System in China.” As we solidify this approval, we’re also laying the groundwork for significant progress across our core target regions. Our commitment to pioneering medical advancements is underscored by significant funding, dedicated to enhancing the lives of individuals worldwide who suffer from heart-related issues.
MicroPort EP aims to initiate a comprehensive rollout of Genesis through its existing sales channels. The companies emphasized that the approval was a crucial component of their comprehensive partnership arrangement. The proposed collaboration aims to enhance Stereotaxis’ robotic platform, integrating robotically guided catheters with the MicroPort EP Columbus 3D navigation system for commercialization.
.
Stereotaxis marks current milestones
This month, the Kansas Health System’s team of physicians successfully treated their first patients utilizing Stereotaxis’ Genesis system. The compact RMN system can boost an individual’s expertise, provide seamless user access, and optimize laboratory space, according to the company.
Stereotaxis submitted its next-generation GenesisX system to the US Food and Drug Administration (FDA) in August. The US Food and Drug Administration (FDA) follows up on the CE mark issued to a product in Europe. The corporation mentioned that its expertise has been utilized to treat more than 150,000 patients worldwide, including those affected by cancer and neurological disorders.
Additionally, a hospital in Kentucky recently acquired the Genesis robotic system. Stereotaxis has made significant progress in its ongoing clinical trial, with notable advancements achieved last autumn.
The article from sibling website was syndicated here. Stereotaxis highlighted in its 2024 performance report
